{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:21:39Z","timestamp":1791217299742,"version":"4.1.0"},"reference-count":37,"publisher":"American Association for Cancer Research (AACR)","issue":"23","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Combination therapy has proven successful in treating a wide variety of aggressive human cancers. Historically, combination treatments have been discovered through serendipity or lengthy trials using known anticancer agents with similar indications. We have used combination high-throughput screening to discover the unexpected synergistic combination of an antiparasitic agent, pentamidine, and a phenothiazine antipsychotic, chlorpromazine. This combination, CRx-026, inhibits the growth of tumor cell lines in vivo more effectively than either pentamidine or chlorpromazine alone. Here, we report that CRx-026 exerts its antiproliferative effect through synergistic dual mitotic action. Chlorpromazine is a potent and specific inhibitor of the mitotic kinesin KSP\/Eg5 and inhibits tumor cell proliferation through mitotic arrest and accumulation of monopolar spindles. Pentamidine treatment results in chromosomal segregation defects and delayed progression through mitosis, consistent with inhibition of the phosphatase of regenerating liver family of phosphatases. We also show that CRx-026 synergizes in vitro and in vivo with the microtubule-binding agents paclitaxel and vinorelbine. These data support a model where dual action of pentamidine and chlorpromazine in mitosis results in synergistic antitumor effects and show the importance of systematic screening for combinations of targeted agents. [Cancer Res 2007;67(23):11359\u201367]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-2235","type":"journal-article","created":{"date-parts":[[2007,12,3]],"date-time":"2007-12-03T19:23:27Z","timestamp":1196709807000},"page":"11359-11367","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action"],"prefix":"10.1158","volume":"67","author":[{"given":"Margaret S.","family":"Lee","sequence":"first","affiliation":[{"name":"1CombinatoRx, Incorporated;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Johansen","sequence":"additional","affiliation":[{"name":"1CombinatoRx, Incorporated;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Progenics Pharmaceuticals, Inc., Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wilson","sequence":"additional","affiliation":[{"name":"1CombinatoRx, Incorporated;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Keegan","sequence":"additional","affiliation":[{"name":"2Gloucester Pharmaceuticals;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Avery","sequence":"additional","affiliation":[{"name":"1CombinatoRx, Incorporated;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Elliott","sequence":"additional","affiliation":[{"name":"3Sirtris Pharmaceuticals, Inc., Cambridge, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis A.","family":"Borisy","sequence":"additional","affiliation":[{"name":"1CombinatoRx, Incorporated;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis T.","family":"Keith","sequence":"additional","affiliation":[{"name":"1CombinatoRx, Incorporated;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,12,3]]},"reference":[{"key":"2022061623193156300_B1","doi-asserted-by":"crossref","unstructured":"Schmoll HJ, Arnold D. Update on capecitabine in colorectal cancer. Oncologist\u20082006; 11: 1003\u20139.","DOI":"10.1634\/theoncologist.11-9-1003"},{"key":"2022061623193156300_B2","doi-asserted-by":"crossref","unstructured":"Cheong K, Spicer J, Chowdhury S, Harper P. Combination therapy versus single agent chemotherapy in non-small cell lung cancer. Expert Opin Pharmacother\u20082005; 6: 1693\u2013700.","DOI":"10.1517\/14656566.6.10.1693"},{"key":"2022061623193156300_B3","doi-asserted-by":"crossref","unstructured":"O'Shaughnessy JA, Blum JL. Capecitabine\/taxane combination therapy: evolving clinical utility in breast cancer. Clin Breast Cancer\u20082006; 7: 42\u201350.","DOI":"10.3816\/CBC.2006.n.012"},{"key":"2022061623193156300_B4","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell\u20082000; 100: 57\u201370.","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"2022061623193156300_B5","unstructured":"Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature\u20082007; 446: 153\u20138."},{"key":"2022061623193156300_B6","doi-asserted-by":"crossref","unstructured":"Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell\u20081996; 87: 159\u201370.","DOI":"10.1016\/S0092-8674(00)81333-1"},{"key":"2022061623193156300_B7","doi-asserted-by":"crossref","unstructured":"von Minckwitz G. Docetaxel\/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother\u20082007; 8: 485\u201395.","DOI":"10.1517\/14656566.8.4.485"},{"key":"2022061623193156300_B8","unstructured":"Raez LE, Lilenbaum R. New developments in chemotherapy for advanced non-small cell lung cancer. Curr Opin Oncol\u20082006; 18: 156\u201361."},{"key":"2022061623193156300_B9","doi-asserted-by":"crossref","unstructured":"Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest\u20082006; 130: 1211\u20139.","DOI":"10.1378\/chest.130.4.1211"},{"key":"2022061623193156300_B10","doi-asserted-by":"crossref","unstructured":"Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction\u2014a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol\u20082006; 3: 448\u201357.","DOI":"10.1038\/ncponc0558"},{"key":"2022061623193156300_B11","doi-asserted-by":"crossref","unstructured":"Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today\u20082005; 10: 139\u201347.","DOI":"10.1016\/S1359-6446(04)03316-1"},{"key":"2022061623193156300_B12","doi-asserted-by":"crossref","unstructured":"Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov\u20082005; 4: 71\u20138.","DOI":"10.1038\/nrd1609"},{"key":"2022061623193156300_B13","doi-asserted-by":"crossref","unstructured":"Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today\u20082007; 12: 34\u201342.","DOI":"10.1016\/j.drudis.2006.11.008"},{"key":"2022061623193156300_B14","doi-asserted-by":"crossref","unstructured":"Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol\u20082001; 1: 370\u20137.","DOI":"10.1016\/S1471-4892(01)00064-9"},{"key":"2022061623193156300_B15","doi-asserted-by":"crossref","unstructured":"Gadde S, Heald R. Mechanisms and molecules of the mitotic spindle. Curr Biol\u20082004; 14: R797\u2013805.","DOI":"10.1016\/j.cub.2004.09.021"},{"key":"2022061623193156300_B16","doi-asserted-by":"crossref","unstructured":"Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer\u20082007; 7: 107\u201317.","DOI":"10.1038\/nrc2049"},{"key":"2022061623193156300_B17","doi-asserted-by":"crossref","unstructured":"Garber K. Divide and conquer: new generation of drugs targets mitosis. J Natl Cancer Inst\u20082005; 97: 874\u20136.","DOI":"10.1093\/jnci\/97.12.874"},{"key":"2022061623193156300_B18","doi-asserted-by":"crossref","unstructured":"Bergnes G, Brejc K, Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem\u20082005; 5: 127\u201345.","DOI":"10.2174\/1568026053507697"},{"key":"2022061623193156300_B19","doi-asserted-by":"crossref","unstructured":"Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell\u20081995; 83: 1159\u201369.","DOI":"10.1016\/0092-8674(95)90142-6"},{"key":"2022061623193156300_B20","doi-asserted-by":"crossref","unstructured":"Sawin KE, LeGuellec K, Philippe M, Mitchison TJ. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature\u20081992; 359: 540\u20133.","DOI":"10.1038\/359540a0"},{"key":"2022061623193156300_B21","doi-asserted-by":"crossref","unstructured":"Trinkle-Mulcahy L, Lamond AI. Mitotic phosphatases: no longer silent partners. Curr Opin Cell Biol\u20082006; 18: 623\u201331.","DOI":"10.1016\/j.ceb.2006.09.001"},{"key":"2022061623193156300_B22","doi-asserted-by":"crossref","unstructured":"Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer\u20082004; 4: 927\u201336.","DOI":"10.1038\/nrc1502"},{"key":"2022061623193156300_B23","doi-asserted-by":"crossref","unstructured":"Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res\u20082007; 5: 1\u201310.","DOI":"10.1158\/1541-7786.MCR-06-0208"},{"key":"2022061623193156300_B24","doi-asserted-by":"crossref","unstructured":"Stephens BJ, Han H, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther\u20082005; 4: 1653\u201361.","DOI":"10.1158\/1535-7163.MCT-05-0248"},{"key":"2022061623193156300_B25","doi-asserted-by":"crossref","unstructured":"Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A\u20082003; 100: 7977\u201382.","DOI":"10.1073\/pnas.1337088100"},{"key":"2022061623193156300_B26","doi-asserted-by":"crossref","unstructured":"Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science\u20081999; 286: 971\u20134.","DOI":"10.1126\/science.286.5441.971"},{"key":"2022061623193156300_B27","doi-asserted-by":"crossref","unstructured":"Funk CJ, Davis AS, Hopkins JA, Middleton KM. Development of high-throughput screens for discovery of kinesin adenosine triphosphatase modulators. Anal Biochem\u20082004; 329: 68\u201376.","DOI":"10.1016\/j.ab.2004.02.032"},{"key":"2022061623193156300_B28","doi-asserted-by":"crossref","unstructured":"Sharp DJ, Rogers GC, Scholey JM. Microtubule motors in mitosis. Nature\u20082000; 407: 41\u20137.","DOI":"10.1038\/35024000"},{"key":"2022061623193156300_B29","doi-asserted-by":"crossref","unstructured":"Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol\u20082000; 150: 975\u201388.","DOI":"10.1083\/jcb.150.5.975"},{"key":"2022061623193156300_B30","unstructured":"Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, Yi T. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther\u20082002; 1: 1255\u201364."},{"key":"2022061623193156300_B31","doi-asserted-by":"crossref","unstructured":"Wang J, Kirby CE, Herbst R. The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem\u20082002; 277: 46659\u201368.","DOI":"10.1074\/jbc.M206407200"},{"key":"2022061623193156300_B32","doi-asserted-by":"crossref","unstructured":"Sokoloff P, Riou JF, Martres MP, Schwartz JC. Presence of dopamine D-2 receptors in human tumoral cell lines. Biochem Biophys Res Commun\u20081989; 162: 575\u201382.","DOI":"10.1016\/0006-291X(89)92349-8"},{"key":"2022061623193156300_B33","doi-asserted-by":"crossref","unstructured":"Marshak DR, Lukas TJ, Watterson DM. Drug-protein interactions: binding of chlorpromazine to calmodulin, calmodulin fragments, and related calcium binding proteins. Biochemistry\u20081985; 24: 144\u201350.","DOI":"10.1021\/bi00322a020"},{"key":"2022061623193156300_B34","doi-asserted-by":"crossref","unstructured":"Matsumoto Y, Maller JL. Calcium, calmodulin, and CaMKII requirement for initiation of centrosome duplication in Xenopus egg extracts. Science\u20082002; 295: 499\u2013502.","DOI":"10.1126\/science.1065693"},{"key":"2022061623193156300_B35","doi-asserted-by":"crossref","unstructured":"Maliga Z, Kapoor TM, Mitchison TJ. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem Biol\u20082002; 9: 989\u201396.","DOI":"10.1016\/S1074-5521(02)00212-0"},{"key":"2022061623193156300_B36","doi-asserted-by":"crossref","unstructured":"Kozlov G, Cheng J, Ziomek E, Banville D, Gehring K, Ekiel I. Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. J Biol Chem\u20082004; 279: 11882\u20139.","DOI":"10.1074\/jbc.M312905200"},{"key":"2022061623193156300_B37","doi-asserted-by":"crossref","unstructured":"Lehar J, Zimmermann GR, Krueger AS, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol\u20082007; 3: 80.","DOI":"10.1038\/msb4100116"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/23\/11359\/2576849\/11359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/23\/11359\/2576849\/11359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:22:05Z","timestamp":1655432525000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/23\/11359\/533863\/The-Novel-Combination-of-Chlorpromazine-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,1]]},"references-count":37,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2007,12,3]]},"published-print":{"date-parts":[[2007,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-2235","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,1]]}}}